查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1907873

軟組織生物製劑市場：市場規模、佔有率、監管、報銷、幹預措施及2036年預測（按細分市場劃分）

Soft Tissue Biologics Market Size by Segments, Share, Regulatory, Reimbursement, Interventions and Forecast to 2036
出版日期: | 出版商: GlobalData | 英文 | 訂單完成後即時交付

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本軟組織生物製劑市場（規模、佔有率、監管、報銷和乾預措施）及2036年預測旨在展現骨科器械治療領域的定量和定性市場趨勢。

軟組織生物製劑用於外科手術，以取代、加強或修復人體撕裂或受損的肌腱和韌帶。軟組織生物製劑市場主要集中在修復前十字韌帶 (ACL)、後十字韌帶 (PCL)、肩袖和跟腱。

骨科軟組織生物製劑廣泛用於治療人體撕裂或受損的肌腱和韌帶。它們源自天然物質，可用於再生和修復肌肉骨骼組織。

微創手術和關節鏡檢查有助於早期介入和治療各種疾病，而再生醫學則促進正常組織的生長、擴張和維持。

針對39個目標國家/地區，我們提供了顏色編碼、資料來源完整的市場模型，其中包含基於流行病學的適應症和乾預量。互動式Excel報表包含價值、數量、產品使用情況、平均售價、市場規模和公司佔有率分析（如有）。此外，分析師的評論和定性見解為定量數據提供了背景資訊。

市場模型亮點包括：

目前可用的軟組織生物製劑器材及不斷變化的競爭格局

  • 對關鍵產業趨勢的深入分析
  • 按細分市場劃分的軟組織生物製劑器材市場年度總收入及2015年至2036年的市場預測。
  • 按細分市場劃分的手術總量、銷售量、平均售價和市場規模的詳細數據。

全球、區域和國家層面的市場洞察 -

  • 除了定性的市場特定資訊外，我們還提供按區域劃分的全球趨勢細分分析。此外，GlobalData 分析師還提供針對特定國家市場的獨特見解。
  • 軟組織生物製劑器材市場的 SWOT 分析。
  • 軟組織生物製劑器材市場的競爭格局與趨勢。

全面、整體的視角，包括醫療保健系統概覽，有助於加深對市場的理解。此外，市場准入部分透過報銷政策和監管環境方面的訊息，能夠更深入地了解市場動態。

  • 各國醫療保健系統概覽。
  • 各國報銷政策。
  • 各國醫療科技監管環境。

我們強大的研究方法和資料來源，能夠提供全面且準確的市場概覽。主要需求方和供應方資訊（包括產業領導企業）已整合到聯合分析模型中。此外，我們也利用真實世界的資料來源來了解市場趨勢，包括政府手術資料庫、醫院採購資料庫和專有線上資料庫。

涵蓋的公司：LifeNet Health Inc.、Xtant Medical Holdings Inc.、ConMed Corp.、AlloSource、Arthrex Inc.、Smith & Nephew Plc、Stryker Corp.、Zimmer Biomet Holdings Inc. 等。

涵蓋的國家：美國、英國、德國、法國、義大利、西班牙、巴西、中國、印度、俄羅斯、日本、澳洲、加拿大、墨西哥、韓國、丹麥、愛爾蘭、荷蘭、紐西蘭、南非、瑞典、瑞士、奧地利、比利時、芬蘭、以色列、挪威、波蘭、葡萄牙、台灣、捷克共和國、希臘、匈牙利、土耳其、埃及、沙烏地阿拉伯、阿拉伯聯合大公國、阿根廷和智利。

範圍

此市場模型提供您在其他任何地方都找不到的關鍵且專業的見解。該模型揭示了特定市場中的定性和定量趨勢。以下人士的必讀之作：

  • 需要深入了解軟組織生物製劑市場，以便制定策略規劃和投資決策的首席行銷長 (CMO)。
  • 需要了解供應鏈關鍵組成部分，以便進行供應商選擇和管理決策的採購主管。
  • 需要深入了解市場，以便識別和評估潛在投資目標的私募股權投資者。

購買理由

模型可幫助您：

  • 審查在研產品，以識別關鍵公司，並制定和設計引進和轉讓許可策略。
  • 透過了解塑造和驅動軟組織生物製劑市場的趨勢，制定您的業務策略。
  • 透過了解關鍵趨勢、創新產品和技術、市場細分以及未來將影響軟組織生物製劑市場的公司，實現收入成長。
  • 透過了解競爭格局並分析市場領導者的市場佔有率，制定有效的銷售和行銷策略。
  • 識別具有潛在強大產品組合的新興公司，並制定有效的應對策略以獲得競爭優勢。
  • 追蹤2015年至2036年全球及各國軟組織生物製劑市場的器材銷售情形。
  • 識別最具整合、投資和策略聯盟機會的市場類別和細分市場，並據此調整您的銷售和行銷工作。
簡介目錄
Product Code: GDME523MM

Soft Tissue Biologics Market Size by Segments, Share, Regulatory, Reimbursement, Interventions and Forecast to 2036 is built to visualize quantitative and qualitative market trends within Orthopedic Devices therapeutic area.

Soft Tissue Biologics are used in surgical Interventions to replace, reinforce, or repair tendons or ligaments that have been torn or damaged in the human body. Soft Tissue Biologics market focuses on the repair of the anterior cruciate ligament (ACL), posterior cruciate ligament (PCL), rotator cuff, and Achilles's tendon.

Orthopedic soft tissue biologics are widely used in Interventions where tendon or ligament is torn or damaged in the human body. They are made from substances that are naturally found in the body and can be used in regeneration and repair of the musculoskeletal tissues.

Minimally invasive surgery and arthroscopy has helped in early intervention and treatment of multiple medical conditions and regenerative medicine has facilitated the in-growth, expansion and preservation of the normal tissue.

Each of the covered 39 countries color-coded and fully-sourced market models are equipped with epidemiology based indications with intervention volumes. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insights offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed Soft Tissue Biologics Devices and evolving competitive landscape -

  • Insightful review of the key industry trends.
  • Annualized total Soft Tissue Biologics Devices market revenue by segment and market outlooks from 2015-2036.
  • Granular data on total Interventions, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights -

  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market.
  • SWOT analysis for Soft Tissue Biologics Devices market.
  • Competitive dynamics insights and trends provided for Soft Tissue Biologics Devices market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

  • Country specific overview of the healthcare system.
  • Country specific reimbursement policies.
  • Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: LifeNet Health Inc, Xtant Medical Holdings Inc, ConMed Corp, AlloSource, Arthrex Inc, Smith & Nephew Plc, Stryker Corp, Zimmer Biomet Holdings Inc, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for:

  • CMO executives who must have deep understanding of the Soft Tissue Biologics marketplace to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products, by identifying key companies.
  • Develop business strategies by understanding the trends shaping and driving Soft Tissue Biologics.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Soft Tissue Biologics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Track device sales in the global and country-specific Soft Tissue Biologics market from 2015-2036.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.